Woodland Cancer Care Center

Summary

Woodland Cancer Care Center is a medical facility located in Michigan City, Indiana. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Non-Small Cell Lung Cancer, Melanoma and other specialties. Woodland Cancer Care Center is involved with conducting 94 clinical trials across 174 conditions. There are 9 research doctors associated with this hospital, such as Nibal Saad, Meghana Raghavendra, Taylor M. Ortiz, and Sameer Z. Ahmed.

Top PIs

Clinical Trials running at Woodland Cancer Care Center

Ovarian Cancer

Lung Cancer

Non-Small Cell Lung Cancer

Breast Cancer

Cancer

Solid Tumors

Colorectal Cancer

Melanoma

Endometrial Cancer

Breast cancer

Targeted Therapy

for Solid Tumors

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.

Recruiting

1 award

Phase 2

17 criteria

Neratinib or Neratinib + Palbociclib

for Cancer

This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors. Neratinib and palbociclib are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of tumor cells. Giving neratinib and palbociclib in combination may shrink or stabilize cancers that over-express a specific biomarker called HER2.

Recruiting

1 award

Phase 2